Frontiers in Oncology
type: Periodical
type: Collection
type: Continuant
publication venue for: Drug repositioning in thyroid cancer: from point mutations to gene fusions
type: Journal
type: Generically Dependent Continuant
type: Information Content Entity
type: Thing
type: Entity
type: Document

Document
type: Class

Drug repositioning in thyroid cancer: from point mutations to gene fusions
type: Continuant
chemicalscas: adagrasib, 2326521-71-3; afatinib, 439081-18-2, 850140-72-6, 850140-73-7; alectinib, 1256580-46-7, 1256589-74-8; alpelisib, 1217486-61-7; amivantamab, 2171511-58-1; brigatinib, 1197953-54-0; cabozantinib, 942407-59-2, 1140909-48-3, 849217-68-1; capmatinib, 1029712-80-8, 1029714-89-3, 1197376-85-4, 1865733-40-9; ceritinib, 1032900-25-6; crizotinib, 877399-52-5; dabrafenib, 1195765-45-7, 1195768-06-9; eltrombopag, 376591-99-0, 443130-00-5, 496775-61-2, 496775-62-3, 2336813-25-1; entrectinib, 1108743-60-7; guanosine triphosphatase, 9059-32-9; ipilimumab, 477202-00-9; lapatinib, 231277-92-2, 388082-78-8, 437755-78-7; larotrectinib, 1223403-58-4, 1223405-08-0; lorlatinib, 1454846-35-5; mitogen activated protein kinase, 142243-02-5; nivolumab, 946414-94-4; osimertinib, 1421373-65-0, 1421373-66-1; pertuzumab, 380610-27-5; phosphatase, 9013-05-2; phosphatidylinositol 3 kinase, 115926-52-8; phosphatidylinositol 3,4,5 trisphosphate 3 phosphatase, 210488-47-4; pioglitazone, 105355-27-9, 111025-46-8, 1266523-09-4, 105390-47-4, 112529-15-4; protein kinase, 9026-43-1; protein serine threonine kinase, ; rituximab, 174722-31-7; sitagliptin, 486460-32-6, 654671-78-0, 654671-77-9, 2088771-60-0, 486459-71-6; sotorasib, 2252403-56-6, 2296729-00-3; suramin, 129-46-4, 145-63-1; tepotinib, 1100598-32-0, 1946826-82-9, 1103508-80-0; trametinib, 1187431-43-1, 871700-17-3; vandetanib, 338992-00-0, 338992-48-6, 443913-73-3
has funding vehicle: Instituto de Salud Pública; Universidad Veracruzana, UV
crisid: 12524
doi: 10.3389/fonc.2024.1407511
most specific type: Article
type: Document
accesstype: Open Access
abstract: The diagnosis of thyroid cancer (TC) has increased dramatically in recent years. Papillary TC is the most frequent type and has shown a good prognosis. Conventional treatments for TC are surgery, hormonal therapy, radioactive iodine, chemotherapy, and targeted therapy. However, resistance to treatments is well documented in almost 20%25 of all cases. Genomic sequencing has provided valuable information to help identify variants that hinder the success of chemotherapy as well as to determine which of those represent potentially druggable targets. There is a plethora of targeted therapies for cancer, most of them directed toward point mutations; however, chromosomal rearrangements that generate fusion genes are becoming relevant in cancer but have been less explored in TC. Therefore, it is relevant to identify new potential inhibitors for genes that are recurrent in the formation of gene fusions. In this review, we focus on describing potentially druggable variants and propose both point variants and fusion genes as targets for drug repositioning in TC. Copyright
e iscopus: 2-s2.0-85193705559
artnum: 1407511
type: Generically Dependent Continuant
type: Entity
related by: authorship_76710
type: Information Content Entity
has publication venue: Frontiers in Oncology
most specific type: Document
freetext keyword: gene fusions; mutations; repurposed drugs; thyroid cancer; variants adagrasib; afatinib; alectinib; alpelisib; amivantamab; brigatinib; cabozantinib; capmatinib; ceritinib; crizotinib; dabrafenib; eltrombopag; entrectinib; ephrin receptor; guanosine triphosphatase; ipilimumab; lapatinib; larotrectinib; lorlatinib; mitogen activated protein kinase; nivolumab; osimertinib; pertuzumab; phosphatase; phosphatidylinositol; phosphatidylinositol 3 kinase; phosphatidylinositol 3,4,5 trisphosphate 3 phosphatase; pioglitazone; protein kinase; protein serine threonine kinase; radioactive iodine; rituximab; sitagliptin; sotorasib; suramin; tepotinib; trametinib; vandetanib; antineoplastic activity; B cell lymphoma; brain metastasis; breast cancer; breast carcinoma; carcinogenesis; case report; cell proliferation; chemotherapy; clinical article; colorectal cancer; cytokine production; drug repositioning; drug therapy; gene; gene fusion; gene mutation; genomic instability; glioma; high throughput sequencing; hormonal therapy; human; leukemia; lung adenocarcinoma; melanoma; metastasis; molecularly targeted therapy; non insulin dependent diabetes mellitus; non small cell lung cancer; NUT midline carcinoma cell line; ovary cancer; point mutation; prognosis; sarcoma; secretory breast carcinoma; sequence analysis; Short Survey; signal transduction; single nucleotide polymorphism; thyroid cancer; tumor associated leukocyte; tumor growth; tumor microenvironment; tumor suppressor gene; uterine cervix cancer
related by: authorship_75637
date time value: article date 12524
volume: 14
type: Thing
type: Article
estado: published

Continuant
type: Class

Entity
type: Class

Generically Dependent Continuant
type: Class

RDF description of Drug repositioning in thyroid cancer: from point mutations to gene fusions - http://orbis.uaslp.mx/vivo/individual/scopus12523
rights: termsOfUse
date: 2026-08-26T23:54:15
publisher: vivo
type: Document

Article
type: Class

Information Content Entity
type: Class

Instituto de Salud Pública; Universidad Veracruzana, UV
type: Relationship
type: BFO_0000020
type: Entity
type: Thing
type: Grant
type: Continuant
funding vehicle for: Drug repositioning in thyroid cancer: from point mutations to gene fusions